江蘇吳中(600200.SH):2019年扣非淨虧損7215.30萬元
格隆匯3月16日丨江蘇吳中(600200.SH)披露2019年年度報告,報告期內,公司實現營收21.10億元,同比增長23.99%;歸屬於上市公司股東的淨利潤6453.37萬元,上年同期為虧損2.86億元;歸屬於上市公司股東的扣除非經常性損益的淨虧損7215.30萬元,上年同期為虧損4.53億元;經營活動現金淨流出1.66億元,上年同期為淨流入3.34億元;基本每股收益0.090元。
報告期內,為集中優勢資源發展公司核心醫藥產業,進一步明確公司的發展戰略和產業佈局,努力打造發展以醫藥為核心的大健康產業,公司完成了房地產業務的剝離工作。
公司醫藥板塊通過全資子公司江蘇吳中醫藥集團有限公司來組織運營,主營業務涉及藥品研發、生產和銷售,擁有兩家藥品生產企業,目前主要產品涵蓋“抗病毒/抗感染、免疫調節、抗腫瘤、消化系統、心血管類”等領域。
公司化工板塊通過全資子公司響水恆利達科技化工有限公司來組織運營。主營業務主要涉及有機顏料、染料及其中間體的研發、生產及銷售,主要生產品種用於生產製造活性染料及有機顏料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.